H. Lundbeck A/S (Lundbeck) reports revenue of DKK 3,563 million for the third quarter of 2012, excluding Lexapro® in the US, an increase of 2% compared to the same period last year. EBITDA and EBIT were DKK 846 million and DKK 661 million respectively, corresponding to an EBITDA margin of 23.4% and an EBIT margin of 18.2%. Profits were affected by the increase in launch costs associated with Lundbeck’s newer products, as well as the loss of revenue from Lexapro due to generic competition.
